Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) delta variant of concern breakthrough infections: Are vaccines failing us?
作者信息
Nowroozi Ali, Rezaei Nima
机构信息
School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
出版信息
Infect Control Hosp Epidemiol. 2022 Nov;43(11):1754-1755. doi: 10.1017/ice.2021.363. Epub 2021 Aug 6.
Abstract
摘要
相似文献
1
Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) delta variant of concern breakthrough infections: Are vaccines failing us?
Infect Control Hosp Epidemiol. 2022 Nov;43(11):1754-1755. doi: 10.1017/ice.2021.363. Epub 2021 Aug 6.
2
SARS-CoV-2 Breakthrough Infections among US Embassy Staff Members, Uganda, May-June 2021.
Emerg Infect Dis. 2022 Jun;28(6):1279-1280. doi: 10.3201/eid2806.220427. Epub 2022 Apr 26.
3
Animal models for studying coronavirus infections and developing antiviral agents and vaccines.
Antiviral Res. 2022 Jul;203:105345. doi: 10.1016/j.antiviral.2022.105345. Epub 2022 May 21.
4
Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines.
Clin Microbiol Infect. 2022 Apr;28(4):596-601. doi: 10.1016/j.cmi.2021.11.023. Epub 2021 Dec 13.
5
Vaccines based on virus-like nano-particles for use against Middle East Respiratory Syndrome (MERS) coronavirus.
Vaccine. 2020 Aug 10;38(36):5742-5746. doi: 10.1016/j.vaccine.2020.07.003. Epub 2020 Jul 11.
6
Duration of viral shedding and culture positivity with postvaccination SARS-CoV-2 delta variant infections.
JCI Insight. 2022 Jan 25;7(2):e155483. doi: 10.1172/jci.insight.155483.
7
Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
EBioMedicine. 2020 May;55:102743. doi: 10.1016/j.ebiom.2020.102743. Epub 2020 Apr 2.
8
Vaccination remains the first choice to control the spread of delta and other variants of severe acute respiratory coronavirus virus 2 (SARS-CoV-2).
Infect Control Hosp Epidemiol. 2022 Nov;43(11):1749-1750. doi: 10.1017/ice.2021.364. Epub 2021 Aug 6.
9
COVID-19: Coronavirus Vaccine Development Updates.
Front Immunol. 2020 Dec 23;11:602256. doi: 10.3389/fimmu.2020.602256. eCollection 2020.
10
[Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future].
Sheng Wu Gong Cheng Xue Bao. 2020 Apr 25;36(4):571-592. doi: 10.13345/j.cjb.200115.
引用本文的文献
1
Delta Variant: The New Challenge of COVID-19 Pandemic, an Overview of Epidemiological, Clinical, and Immune Characteristics.
Acta Biomed. 2022 Mar 14;93(1):e2022179. doi: 10.23750/abm.v93i1.12210.
2
Impact of the Double Mutants on Spike Protein of SARS-CoV-2 B.1.617 Lineage on the Human ACE2 Receptor Binding: A Structural Insight.
Viruses. 2021 Nov 17;13(11):2295. doi: 10.3390/v13112295.
3
The global transmission of new coronavirus variants.
Environ Res. 2022 Apr 15;206:112240. doi: 10.1016/j.envres.2021.112240. Epub 2021 Oct 22.
本文引用的文献
1
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. Reply.
N Engl J Med. 2021 Dec 16;385(25):e92. doi: 10.1056/NEJMc2113090. Epub 2021 Nov 10.
2
SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination.
Cell Rep. 2021 Jul 20;36(3):109415. doi: 10.1016/j.celrep.2021.109415. Epub 2021 Jun 29.
3
Efficacy and Safety of COVID-19 Vaccines in Phase III Trials: A Meta-Analysis.
Vaccines (Basel). 2021 Jun 1;9(6):582. doi: 10.3390/vaccines9060582.
4
SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.
Lancet. 2021 Jun 26;397(10293):2461-2462. doi: 10.1016/S0140-6736(21)01358-1. Epub 2021 Jun 14.
Zotero 插件